Cargando…

Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer

In this study, we collected genes related to energy metabolism, used gene expression data from public databases to classify molecular subtypes of colon cancer (COAD) based on the genes related to energy metabolism, and further evaluated the relationships between the molecular subtypes and prognosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yihang, Chen, Ji, Wang, Jue, Xu, Ming, Zhang, Yunpeng, Sun, Peng, Liang, Leilei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251179/
https://www.ncbi.nlm.nih.gov/pubmed/32509568
http://dx.doi.org/10.3389/fonc.2020.00595
_version_ 1783538911268569088
author Yuan, Yihang
Chen, Ji
Wang, Jue
Xu, Ming
Zhang, Yunpeng
Sun, Peng
Liang, Leilei
author_facet Yuan, Yihang
Chen, Ji
Wang, Jue
Xu, Ming
Zhang, Yunpeng
Sun, Peng
Liang, Leilei
author_sort Yuan, Yihang
collection PubMed
description In this study, we collected genes related to energy metabolism, used gene expression data from public databases to classify molecular subtypes of colon cancer (COAD) based on the genes related to energy metabolism, and further evaluated the relationships between the molecular subtypes and prognosis and clinical characteristics. Differential expression analysis of the molecular subtypes yielded 1948 differentially expressed genes (DEGs), whose functions were closely related to the occurrence and development of cancer. Based on the DEGs, we constructed a 4-gene prognostic risk model and identified the high expression of FOXD4, ENPEP, HOXC6, and ALOX15B as a risk factor associated with a high risk of developing COAD. The 4-gene signature has strong robustness and a stable predictive performance in datasets from different platforms not only in patients with early COAD but also in all patients with colon cancer. The enriched pathways of the 4-gene signature in the high- and low-risk groups obtained by GSEA were significantly related to the occurrence and development of colon cancer. Moreover, the results of qPCR, immunohistochemistry staining and Western blot assay revealed that FOXD4, ENPEP, HOXC6, and ALOX15B are over expressed in CRC tissues and cells. These results suggesting that the signature could potentially be used as a prognostic marker for clinical diagnosis.
format Online
Article
Text
id pubmed-7251179
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72511792020-06-05 Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer Yuan, Yihang Chen, Ji Wang, Jue Xu, Ming Zhang, Yunpeng Sun, Peng Liang, Leilei Front Oncol Oncology In this study, we collected genes related to energy metabolism, used gene expression data from public databases to classify molecular subtypes of colon cancer (COAD) based on the genes related to energy metabolism, and further evaluated the relationships between the molecular subtypes and prognosis and clinical characteristics. Differential expression analysis of the molecular subtypes yielded 1948 differentially expressed genes (DEGs), whose functions were closely related to the occurrence and development of cancer. Based on the DEGs, we constructed a 4-gene prognostic risk model and identified the high expression of FOXD4, ENPEP, HOXC6, and ALOX15B as a risk factor associated with a high risk of developing COAD. The 4-gene signature has strong robustness and a stable predictive performance in datasets from different platforms not only in patients with early COAD but also in all patients with colon cancer. The enriched pathways of the 4-gene signature in the high- and low-risk groups obtained by GSEA were significantly related to the occurrence and development of colon cancer. Moreover, the results of qPCR, immunohistochemistry staining and Western blot assay revealed that FOXD4, ENPEP, HOXC6, and ALOX15B are over expressed in CRC tissues and cells. These results suggesting that the signature could potentially be used as a prognostic marker for clinical diagnosis. Frontiers Media S.A. 2020-05-20 /pmc/articles/PMC7251179/ /pubmed/32509568 http://dx.doi.org/10.3389/fonc.2020.00595 Text en Copyright © 2020 Yuan, Chen, Wang, Xu, Zhang, Sun and Liang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yuan, Yihang
Chen, Ji
Wang, Jue
Xu, Ming
Zhang, Yunpeng
Sun, Peng
Liang, Leilei
Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer
title Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer
title_full Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer
title_fullStr Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer
title_full_unstemmed Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer
title_short Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer
title_sort development and clinical validation of a novel 4-gene prognostic signature predicting survival in colorectal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251179/
https://www.ncbi.nlm.nih.gov/pubmed/32509568
http://dx.doi.org/10.3389/fonc.2020.00595
work_keys_str_mv AT yuanyihang developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer
AT chenji developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer
AT wangjue developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer
AT xuming developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer
AT zhangyunpeng developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer
AT sunpeng developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer
AT liangleilei developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer